News
ICCC
6.24
+2.16%
0.13
Immucell Announces Entry Into Material Definitive Agreement
TipRanks · 6d ago
ImmuCell Corporation beschließt neue Vergütungsvereinbarungen für Führungskräfte
Reuters · 6d ago
ImmuCell Sets New Executive Pay Packages and Performance Incentives
Reuters · 6d ago
Weekly Report: what happened at ICCC last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at ICCC last week (0119-0123)?
Weekly Report · 01/26 10:21
Weekly Report: what happened at ICCC last week (0112-0116)?
Weekly Report · 01/19 10:27
Niche Focus & Regulation Shape the Future of Healthcare Firms
NASDAQ · 01/15 16:24
Weekly Report: what happened at ICCC last week (0105-0109)?
Weekly Report · 01/12 10:27
IMMUCELL CORP: DOES NOT EXPECT THAT CHARGES WILL RESULT IN MATERIAL FUTURE CASH EXPENDITURES - SEC FILING
Reuters · 01/08 21:56
Immucell Announces Impairment Charges and Strategic Refocus
TipRanks · 01/08 21:30
ImmuCell reports preliminary Q4 results
Seeking Alpha · 01/08 21:28
ImmuCell Q4 preliminary sales dip
Reuters · 01/08 21:27
Immucell reports preliminary Q4 revenue $7.6M
TipRanks · 01/08 21:20
ImmuCell Reports Q4 Preliminary Net Sales Of $7.6M; Domestic Sales Were $7.0M In 2025, An 8.7% Increase Compared To 2024
Benzinga · 01/08 21:10
*ImmuCell Announces Preliminary, Unaudited Sales Results for 4Q, FY25
Dow Jones · 01/08 21:08
*Immucell Sees 4Q Sales $7.6M >ICCC
Dow Jones · 01/08 21:07
*Immucell Sees FY Sales $27.6M >ICCC
Dow Jones · 01/08 21:07
ImmuCell Reports 2025 Sales of $27.7 Million with Strong Tri-Shield Growth
Reuters · 01/08 21:06
IMMUCELL ANNOUNCES PRELIMINARY, UNAUDITED SALES RESULTS FOR Q4 AND FULL YEAR OF 2025
Reuters · 01/08 21:05
IMMUCELL CORPORATION FY PRODUCT SALES USD 7.6 MILLION
Reuters · 01/08 21:05
More
Webull provides a variety of real-time ICCC stock news. You can receive the latest news about Immucell through multiple platforms. This information may help you make smarter investment decisions.
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).